Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients
Not Applicable
- Conditions
- Hyperlipidemia.Disorders of lipoprotein metabolism and other lipidaemias
- Registration Number
- IRCT2014030611375N2
- Lead Sponsor
- Shiraz University of Midical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Inclusion Criteria: Patients with diagnosed type2 diabetes for at leat 2 years and also with either plasma TG level more 150 mg/dL or total cholestrol level more 200 mg/dL or LDL between 130-200 or HDL less 50 in female and less 40 in male; Patients who received maximum 2 oral diabetes medications.
Exclusion Criteria
Patients who have a history of chronic or metabolic diseases, or regularly use medication (Fibrate and HMG-COA Reductase inhibitor) or supplements known to affect blood lipids; Patients who have to receive antihyperlipidemic agents for example CAD patients; Patients who were currently received insulin therapy.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Triglyceride. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique).;Low-density lipoprotein (LDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique).;High-density lipoprotein (HDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (dextran magnesium sulfate).;Total cholesterol. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique).
- Secondary Outcome Measures
Name Time Method Body Mass Index. Timepoint: Before and 2 months after intervention. Method of measurement: By BMI Formula.;Systolic Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer.;Diastol Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer.